<DOC>
	<DOCNO>NCT01455779</DOCNO>
	<brief_summary>The purpose study demonstrate treatment efficacy Lyrette® System woman likely treated office set condition stress urinary incontinence , secondary urethral hypermobility .</brief_summary>
	<brief_title>Lyrette : Renewing Continence Objective Subjective Efficacy Study</brief_title>
	<detailed_description>This prospective , open-label , single arm clinical study evaluate Lyrette System ( formerly Renessa System ) population likely treat physician 's office .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Age 35 60 year Female gender Ability complete study requirement Body Mass Index ≤ 35 Incontinence Quality Life score ( IQOL ) ≥ 55 Leak Point Pressure ( LPP ) ≥ 90 cm H2O Maximal Urethral Closure Pressure ( MUCP ) ≥ 45 cm H2O 3 to10 stress leak record 3 day void diary Clinical history stress urinary incontinence ≥ 12 month Clinical diagnosis stress urinary incontinence study physician Clinical diagnosis mixed incontinence predominant stress component . Clinical diagnosis bladder outlet hypermobility study physician Has fail conservative therapy ( Kegels , biofeedback ) and/or receive conservative therapy period least 3 month prior enrollment study . Medical Epidemiologic , Social Aspects Aging ( MESA ) stress symptom percentage score great urge symptom percentage score Postvoid residual ≤ 100 cc Stage II low pelvic organ prolapse Urethral length ≥ 3 cm Is current smoker If subject child , least 1 year elapse child birth cessation breastfeed least 3 month , enrollment . ASA III IV classification Current plan pregnancy within next 12 month Clinical diagnosis detrusor overactivity urodynamic evaluation Clinical diagnosis mixed urinary incontinence predominant urge component Clinical diagnosis primary urge urinary incontinence Clinical diagnosis gravitational loss Stage III , IV Pelvic Organ Prolapse Less 2 gram urine leakage 1 hour stress pad test Previous surgery , RF microremodeling , injection bulk agent specifically treatment urinary incontinence Current incontinence treatment electrical stimulation , biofeedback , and/or medication Previous urethral and/or bladder surgery ( exclude diagnostic endoscope ) Current urinary tract infection History chronic urinary tract infection History recurrent pyelonephritis History interstitial cystitis History upper low urinary tract neoplasm History upper low anatomic urinary tract abnormality disorder History acute chronic renal failure Coagulopathy Immunosuppression ( pathological medication induce ) Collagen vascular disease ( scleroderma , etc . ) Presence pacemaker , AICD , electrical health maintenance device , bladder neuromodulation device . History COPD obstructive pulmonary disease Life expectancy &lt; 12 month Knowingly relocate practice area within 12 month initiation study</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Stress Urinary Incontinence</keyword>
	<keyword>Incontinence</keyword>
	<keyword>SUI</keyword>
	<keyword>Renessa</keyword>
</DOC>